BRIEF-Gemini reports Q1 net loss per share of $0.04
* Now expecting revenue for 2017 to be less than 2016 but expects activity to pick up in second half of 2017 into 2018 Source text for Eikon: Further company coverage:
April 28 The U.S. Food and Drug Administration on Friday approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML).
AML is a rapidly progressing cancer, which forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.
Rydapt has secured approval for adults with newly diagnosed AML that have a specific genetic mutation called FLT3, in combination with chemotherapy, the FDA said. (Reporting by Natalie Grover in Bengaluru)
* Ironhorse announces Q1 2017 financial and operating results